Select a medication above to begin.
Fasenra
benralizumab
Adult Dosing .
Dosage forms: INJ (auto-injector): 30 mg; INJ (pre-filled syringe): 30 mg per mL
severe asthma, maintenance tx
- [30 mg SC q8wk]
- Start: 30 mg SC q4wk x3 doses; Info: for add-on tx in pts w/ eosinophilic phenotype
eosinophilic granulomatosis w/ polyangiitis
- [30 mg SC q4wk]
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (auto-injector): 30 mg; INJ (pre-filled syringe): 10 mg per 0.5 mL, 30 mg per mL
severe asthma, maintenance tx
- [6-11 yo, <35 kg]
- Dose: 10 mg SC q8wk; Start: 10 mg SC q4wk x3 doses; Info: for add-on tx in pts w/ eosinophilic phenotype
- [6-11 yo, >35 kg]
- Dose: 30 mg SC q8wk; Start: 30 mg SC q4wk x3 doses; Info: for add-on tx in pts w/ eosinophilic phenotype
- [12 yo and older]
- Dose: 30 mg SC q8wk; Start: 30 mg SC q4wk x3 doses; Info: for add-on tx in pts w/ eosinophilic phenotype
renal dosing
- [see below]
- CrCl >30: no adjustment; CrCl <30: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- status asthmaticus
- asthma, acute
- bronchospasm, acute
- caution: helminth infection risk
Drug Interactions .
Overview
benralizumab
IL-5 antagonist
-
None
No significant interactions known or found for this drug. Caution always advised with multiple medications.
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylaxis
- helminth infection
Common Reactions
- headache
- pharyngitis
- fever
- hypersensitivity rxn
- injection site rxn
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy, esp. in 3rd trimester; no human data available, though likely to cross placenta in 3rd trimester based on human data w/ other monoclonal antibodies; no known risk of fetal harm based on animal data up to 310x MRHD
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available to assess risk of infant harm or effects on milk production
Pharmacology .
Metabolism: unknown; CYP450: unknown
Excretion: non-renal; Half-life: 15.5 days
Subclass: Interleukin-5 (IL-5) Antagonists
Mechanism of Action
exact mechanism of action unknown; binds to interleukin-5 receptor, reducing eosinophil production and survival (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.